High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C.

Abstract:

:Many patients chronically infected by hepatitis C virus (HCV) experience symptoms like fatigue, dyspnea and reduced physical activity. However, in many patients, these symptoms are not proportional to the liver involvement and could resemble symptoms of chronic heart failure. To our knowledge, no study evaluated serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) in a large series of patients with HCV chronic infection (HCV+). Serum NT-proBNP was assayed in 50 patients HCV+ and in 50 sex- and age-matched controls. HCV+ patients showed significantly higher mean NT-proBNP level than controls (P = 0.001). By defining high NT-proBNP level as a value higher than 125 pg/mL (the single cut-off point for patient under 75 years of age), 34% HCV+ and 6% controls had high NT-proBNP (Fisher exact test; P < 0.001). With a cut-off point of 300 pg/mL (used to rule out chronic heart failure in patients under 75 years of age) 10% HCV+ and 0 controls had high NT-proBNP (Fisher exact test; P = 0.056). With a cut-off point of 900 pg/mL (used for ruling in chronic heart failure in patients with age 50-75) 8% HCV+ patients and 0 controls had high NT-proBNP (Fisher exact test; P = 0.12). The study demonstrates high levels of circulating NT-proBNP in HCV+ patients compared to healthy controls. The increase of NT-proBNP may indicate the presence of a sub-clinical cardiac dysfunction. Further prospective studies quantifying these symptoms in correlation with echocardiography are needed to confirm this association.

journal_name

J Viral Hepat

authors

Antonelli A,Ferri C,Ferrari SM,Colaci M,Sebastiani M,Zignego AL,Ghiri E,Goglia F,Fallahi P

doi

10.1111/j.1365-2893.2009.01237.x

subject

Has Abstract

pub_date

2010-12-01 00:00:00

pages

851-3

issue

12

eissn

1352-0504

issn

1365-2893

pii

JVH1237

journal_volume

17

pub_type

杂志文章
  • Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.

    abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1997.tb00180.x

    authors: Milich DR

    更新日期:1997-01-01 00:00:00

  • Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.

    abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12427

    authors: Ogawa E,Furusyo N,Dohmen K,Kajiwara E,Kawano A,Nomura H,Takahashi K,Satoh T,Azuma K,Nakamuta M,Koyanagi T,Kotoh K,Shimoda S,Hayashi J,Kyushu University Liver Disease Study (KULDS) Group.

    更新日期:2015-12-01 00:00:00

  • TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

    abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01439.x

    authors: Petta S,Di Marco V,Di Stefano R,Cabibi D,Cammà C,Marchesini G,Craxì A

    更新日期:2011-07-01 00:00:00

  • Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

    abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2005.00682.x

    authors: Bräu N,Bini EJ,Currie S,Shen H,Schmidt WN,King PD,Ho SB,Cheung RC,Hu KQ,Anand BS,Simon FR,Aytaman A,Johnson DP,Awad JA,Ahmad J,Mendenhall CL,Pedrosa MC,Moseley RH,Hagedorn CH,Waters B,Chang KM,Morgan TR,Rossi

    更新日期:2006-04-01 00:00:00

  • Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

    abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12047

    authors: Seto WK,Tsang OT,Liu K,Chan JM,Wong DK,Fung J,Lai CL,Yuen MF

    更新日期:2013-07-01 00:00:00

  • Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.

    abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12838

    authors: Nam JY,Chang Y,Cho H,Kang SH,Cho YY,Cho EJ,Lee JH,Yu SJ,Yoon JH,Kim YJ

    更新日期:2018-05-01 00:00:00

  • Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

    abstract::Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1997.00062.x

    authors: Farrell G,Cooksley WG,Dudley FJ,Watson K

    更新日期:1997-09-01 00:00:00

  • Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

    abstract::Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12059

    authors: Wang GQ,Ding YP,Dong YH

    更新日期:2013-04-01 00:00:00

  • Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.

    abstract::The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin <2.0 mg/dL]. Four groups of patients categorized by HBeAg status and treatment regimens were studied sinc...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2011.01469.x

    authors: Chen CC,Wang PC,Chang HW,Chen CF

    更新日期:2012-03-01 00:00:00

  • Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.

    abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01486.x

    authors: Togo S,Arai M,Tawada A,Chiba T,Kanda T,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2011-10-01 00:00:00

  • Exposure to hepatitis B and C of tattooists in Victoria in 1984.

    abstract::Although tattooing is recognized as a risk factor for transmission of hepatitis C, the efficiency with which transmission occurs is unknown. Sera stored from a serosurvey of tattooists undertaken in 1984 to test for human immunodeficiency virus (HIV) provided the opportunity to determine the prevalence of serological ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1997.tb00216.x

    authors: Thompson SC,Goudey RE,Breschkin AM,Carnie J,Catton M

    更新日期:1997-03-01 00:00:00

  • The non-structural 5A protein of hepatitis C virus.

    abstract::The non-structural (NS)5A protein of hepatitis C virus (HCV) is cleaved, after translation, by the NS3-encoded zinc-dependent serine proteinase, from the NS4B protein upstream and the NS5B protein downstream. The released, mature NS5A protein is a 56 000 MW phosphoprotein (p56), which also exists within infected cells...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00185.x

    authors: Pawlotsky JM,Germanidis G

    更新日期:1999-09-01 00:00:00

  • Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.

    abstract::It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analysed data from patie...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12723

    authors: Kim GA,Han S,Kim HD,An J,Lim YS

    更新日期:2017-11-01 00:00:00

  • The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.

    abstract::Hepatocellular carcinoma (HCC) is the most common complication of HCV infection leading to liver transplantation. We evaluated the impact of aetiology of liver disease on patient and graft survival following liver transplantation for HCC. From the Scientific Registry of Transplant Recipients (2002-2011), all adults wh...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12449

    authors: Younossi ZM,Stepanova M,Saab S,Ahmed A,Lam B,Srishord M,Venkatesan C,Wai H,Henry L

    更新日期:2016-01-01 00:00:00

  • The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.

    abstract::The ECHO model was developed to expand access to medical care for populations with HCV infection in underserved areas. We aimed to compare HCV treatment outcomes in community-based clinics with the Austral University Hospital (AUH) and to assess improvement in physician knowledge and skills. In October 2015, we establ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13172

    authors: Mendizabal M,Ridruejo E,Ceballos S,Sixto M,Billordo A,Gadea C,Mengarelli S,Alonso C,Palazzo A,De María L,Bruno A,Perez D,Piñero F,Deltrozzo V,Mendoza C,Figueroa S,Manero E,Villa M,Barreyro F,Moreno V,Vilar J,Mur

    更新日期:2019-11-01 00:00:00

  • Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus.

    abstract::To evaluate, among 70 hepatitis C virus (HCV)-monoinfected and 36 human immunodeficiency virus (HIV)-coinfected naïve patients with genotypes 1/4 receiving weight-adjusted pegylated interferon-alpha-2b/ribavirin, viral kinetics and the feasibility to predict treatment failure measuring early HCV-RNA decreases. HCV-RNA...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00710.x

    authors: Moreno A,Bárcena R,García-Garzón S,Moreno L,Quereda C,Muriel A,Zamora J,Mateos ML,Pérez-Elías MJ,Antela A,Diz S,Moreno A,Moreno S

    更新日期:2006-07-01 00:00:00

  • Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection.

    abstract::Hepatitis B virus (HBV) infection induces a wide range of chronic liver injury. The mechanism by which HBV evades the immune surveillance system remains obscure. Plasmacytoid dendritic cells (pDCs) seem to be the major endogenous interferon (IFN)-alpha producers and represent one of the most important cell types in th...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00819.x

    authors: Wang K,Fan X,Fan Y,Wang B,Han L,Hou Y

    更新日期:2007-04-01 00:00:00

  • Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.

    abstract::Socio-demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV-infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12535

    authors: Giudici F,Bertisch B,Negro F,Stirnimann G,Müllhaupt B,Moradpour D,Cerny A,Keiser O,Swiss Hepatitis C Cohort Study.

    更新日期:2016-09-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

    abstract::Summary.  Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Bo...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01613.x

    authors: Ahmed F

    更新日期:2013-05-01 00:00:00

  • Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily.

    abstract::Oral therapy for chronic hepatitis B remains suboptimal. Mathematical modelling of viral decay kinetics to rapidly assess potential antiviral regimens has proved valuable for human immunodeficiency virus and cytomegalovirus. We defined the kinetics of viral replication in 10 chronic hepatitis B patients randomized to ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2004.00523.x

    authors: Wang CC,Holte S,Huang ML,Sacks SL,Engelberg R,Ferrenberg J,Shuhart M,Corey L

    更新日期:2004-09-01 00:00:00

  • Estimating paediatric hepatitis C prevalence in the United States.

    abstract::Over 70 million individuals are infected with hepatitis C virus (HCV) worldwide. Yet most prevalence data are in the adult population, with little focus on paediatrics, partially due to the scarcity of public data. The objective of this paper is to examine HCV prevalence in children by estimating prevalence rates amon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13377

    authors: Rahal H,Boutros S,Farhat M,Kullar R,Rahal K,Saab S

    更新日期:2020-12-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Adefovir serum levels do not differ between responders and nonresponders.

    abstract::Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined pat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01404.x

    authors: Deterding K,Naesens L,Buti M,Janssen H,Kirschner J,Guerrero A,Reijnders J,Neyts J,Zoulim F,Wedemeyer H

    更新日期:2011-07-01 00:00:00

  • Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.

    abstract::Clinical and experimental studies have demonstrated that connective-tissue growth factor (CTGF) expression is increased in fibrotic human liver and experimental animal models of liver fibrogenesis. CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01110.x

    authors: Kovalenko E,Tacke F,Gressner OA,Zimmermann HW,Lahme B,Janetzko A,Wiederholt T,Berg T,Müller T,Trautwein C,Gressner AM,Weiskirchen R

    更新日期:2009-09-01 00:00:00

  • Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

    abstract::A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studie...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2005.00651.x

    authors: Micallef JM,Kaldor JM,Dore GJ

    更新日期:2006-01-01 00:00:00

  • Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.

    abstract::Reports have described a decrease in glomerular filtration rate (eGFR) associated with tenofovir disoproxil fumarate (TDF) use in HIV positive individuals. However, no study has examined renal function over a prolonged period in HIV/hepatitis B virus (HBV) co-infected patients. We assessed the long-term durability and...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01084.x

    authors: Tan LK,Gilleece Y,Mandalia S,Murungi A,Grover D,Fisher M,Atkins M,Nelson M

    更新日期:2009-07-01 00:00:00

  • Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

    abstract::Chronic hepatitis C virus (HCV) infection eventually leads to cirrhosis in 20-30% of patients and to hepatocellular carcinoma (HCC) in 1-5% of patients. Rates of sustained virological response with standard interferon-alpha (IFN-alpha) are low in patients without cirrhosis (generally < 20%) and are even lower in those...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00229.x

    authors: Zeuzem S

    更新日期:2000-09-01 00:00:00

  • Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project.

    abstract::Italy is one of the countries on track with the WHO's agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named 'Telepass' project, for patients exposed to ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13465

    authors: Ponziani FR,Santopaolo F,Siciliano M,De Belvis AG,Tortora A,Mora V,Fanali C,Morsella A,Balducci F,Vetrugno G,D'Alfonso ME,Cambieri A,Cauda R,Bellantone R,Sanguinetti M,Pompili M,Gasbarrini A

    更新日期:2021-01-09 00:00:00

  • Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.

    abstract::The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated. The aim of this study was to evaluate the efficacy of lamivudine re-treatment in relapsed patients. Among 192 patients who had achieved HBeAg seroconversion wi...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2005.00606.x

    authors: Shin JW,Park NH,Park JH,Park JH,Jeong ID,Bang SJ,Joo KR,Kim DH

    更新日期:2005-07-01 00:00:00